Track topics on Twitter Track topics that are important to you
Chiesi Farmaceutici SpA Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.
This uptotheminute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Business description A detailed description of the company's operations and business divisions.
Corporate strategy GlobalData's summarization of the company's business strategy.
SWOT analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list of key locations and subsidiaries of the company, including contact details.
Key manufacturing facilities A list of key manufacturing facilities of the company.
Chiesi Farmaceutici SpA Chiesi researches, develops, produces and commercializes novel medicines with focus on respiratory, neonatology, rare disease and special care therapeutic areas. The company provides products for the treatment of chronic obstructive pulmonary disease COPD, asthma, rheumatoid arthritis, ankylosing spondylitis, hypertension, percutaneous coronary intervention, apnoea of prematurity, respiratory distress syndrome RDS, lipoprotein lipase deficiency LPLD, limbal stem cell deficiency LSCD, inflammatory bowel diseases and renal and liver failure solid organ transplant SOT. The company operates production sites in Parma, Italy; Blois, France; and Santana De Parnaiba, Brazil; and carries out research and development RD activities at its new RD center in Parma and at laboratories in Paris, Chippenham UK, Cary US, Lidingo Sweden and Hillerod Denmark. Chiesi is headquartered in Parma, Italy.
Chiesi Farmaceutici SpA Key Recent Developments
Sep 03,2016: The Lancet Publishes The Results Of Chiesi Farmaceutici Trilogy Study
May 03,2016: Kamada Receives Two Milestone Payments under Strategic Agreements with Chiesi Farmaceutici and Baxalta
Mar 30,2016: 80 Years of Innovation and Success in Healthcare: Chiesi Reports Significant International Growth in 2015
Reasons to Buy
Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.
Understand and respond to your competitors' business structure and strategies with GlobalData's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs. They're usually caused by viruses, but they can also ...
COPD (chronic obstructive pulmonary disease)
COPD (chronic obstructive pulmonary disease) is used for a number of conditions including chronic bronchitis and emphysema, which all lead to the airways in the lungs becoming damaged and thus narrower, making inhalation and exhalation harder...